Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases.

Product Candidates
We are developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn’s disease, including for patients with a prospectively defined biomarker who may benefit from a precision approach utilizing RVT-3101.
Our Team
Filter by Role

Frank Torti, MD
Chairman and Chief Executive Officer

Bittoo Kanwar, MD
Chief Medical Officer

Joe Bishop
Chief Financial Officer

Amy Mahery
Chief Commercial Officer

Srini Ramanathan, PhD
Chief Development Officer

Navneet Alag
Governance

Ameer Basrai
CMC

Jason Chamberlain, PhD
Nonclinical Development

Kristin Clement, PhD
CMC

Caroline Cooper
Clinical Operations

Xiao-Dong Chen, PhD
CMC

Jean Dodge, PharmD
Pharmacovigilance

Craig Dyar, PhD
Quality

Eric Gaukel
Nonclinical Development

Abe Germansderfer
CMC

Hilary Hafeken
Regulatory

Anne Hansen
Data Management

Coleenique Jefferson
Clinical Operations

Reed Johnson
Program Management

Jeremy Lathen
Program Management

Li-Yin Lee, PhD
Biostatistics

Peter Noolandi
CMC

Lee O’Brien, PhD
Regulatory

Marie Parrish, PhD
Regulatory

Dan Patterson, PhD
CMC

Sudhir Penugonda, MD
Clinical Development

Chrissa Rizk
Clinical Operations

Victoria Silva, PhD
CMC

Winston Su, PharmD
Regulatory

Suzanne Vyvoda
Clinical Operations

Eric Wasserstrum
Governance

Emily Weng, ScD
Biometrics & Data Science

Agata Woldanski
Data Management

Yan Xin, PhD
Clinical Pharmacology

Frank Torti, MD
Chairman and Chief Executive Officer

Irena Melnikova, PhD
Director

Eric Venker, MD
Director
